<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5909">
  <stage>Registered</stage>
  <submitdate>26/10/2015</submitdate>
  <approvaldate>26/10/2015</approvaldate>
  <nctid>NCT02609828</nctid>
  <trial_identification>
    <studytitle>Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy.</studytitle>
    <scientifictitle>A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of The Subcutaneous Administration Of Tanezumab (Pf-04383119) In Subjects With Cancer Pain Predominantly Due To Bone Metastasis Receiving Background Opioid Therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2013-002223-42</secondaryid>
    <secondaryid>A4091061</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neoplasm Metastasis</healthcondition>
    <healthcondition>Musculoskeletal Pain</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Any cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Tanezumab

Experimental: Arm 1 - Tanezumab 20 mg subcutaneously

Placebo Comparator: Arm 2 - Placebo matched to active treatment subcutaneously


Treatment: drugs: Tanezumab
Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline in daily average pain intensity in index bone metastasis cancer pain site - Change from Baseline to Week 8 in the daily average pain intensity Numerical Rating Score (NRS) in the index bone metastasis cancer pain site.</outcome>
      <timepoint>8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in daily average pain intensity in index bone metastasis cancer pain site - Change from Baseline to Weeks 1, 2, 4, 6, 12, 16 and 24 in the daily average pain intensity NRS score in the index bone metastasis cancer pain site.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in daily worst pain intensity in index bone metastasis cancer pain site - Change from Baseline to Weeks 1, 2, 4, 6, 8, 12, 16 and 24 in the daily worst pain intensity NRS score in the index bone metastasis cancer pain site.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in weekly average pain intensity in non-index cancer pain sites - Change from Baseline to Weeks 1, 2, 4, 6, 8, 12, 16 and 24 in the weekly average pain intensity NRS score in non-index cancer pain sites.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in weekly worst pain intensity in non-index cancer pain sites - Change from Baseline to Weeks 1, 2, 4, 6, 8, 12, 16 and 24 in the weekly worst pain intensity NRS score in non-index cancer pain sites.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in daily average pain intensity in non-index visceral cancer pain sites - Change from Baseline to Weeks 1, 2, 4, 6, 8, 12, 16 and 24 in the daily average pain intensity NRS score in the non-index visceral cancer pain sites.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in daily worst pain intensity in non-index visceral cancer pain sites - Change from Baseline to Weeks 1, 2, 4, 6, 8, 12, 16 and 24 in the daily worst pain intensity NRS score in the non-index visceral cancer pain sites.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in Brief Pain Inventory (BPI) average pain score - Change from Baseline to Weeks 2, 4, 8, 16 and 24 in the Brief Pain Inventory (BPI) average pain scores obtained at study visits.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in BPI worst pain score - Change from Baseline to Weeks 2, 4, 8, 16 and 24 in the BPI worst pain scores obtained at study visits.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Response as defined by a 30%, 50%, 70%, and 90% reduction from Baseline in the daily average and daily worst pain intensity NRS score in the index bone metastasis cancer pain site - Response as defined by a 30%, 50%, 70%, and 90% reduction from baseline in the daily average and daily worst pain intensity NRS score in the index bone metastasis cancer pain site at Weeks 1, 2, 4, 6, 8, 12, 16 and 24.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in Patient's Global Assessment of Cancer Pain - Change from Baseline in Patient's Global Assessment of Cancer Pain at Weeks 2, 4, 8, 16 and 24.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Response defined as an improvement of 2 points in Patient's Global Assessment of Cancer Pain - Response defined as an improvement of 2 points in Patient's Global Assessment of Cancer Pain at Weeks 2, 4, 8, 16 and 24.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the BPI Pain Interference with Function composite score and individual pain interference item scores - Change from Baseline to Weeks 2, 4, 8, 16 and 24 in the BPI Pain Interference with Function Composite Score and individual pain interference item scores obtained at study visits.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>EuroQol 5 Dimension (EQ-5D-5L) dimensions and overall health utility score - EuroQol 5 Dimension (EQ-5D-5L) dimensions and overall health utility score at Baseline and Weeks 8, 16 and 24.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Average daily total opioid consumption (in mg of morphine equivalent doses) - Average daily total opioid consumption (in mg of morphine equivalent doses) at Weeks 1, 2, 4, 6, 8, 12, 16 and 24.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Average number of doses of rescue medication required per week - Average number of doses of rescue medication required per week at Weeks 1, 2, 4, 6, 8, 12, 16 and 24.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in weekly Opioid-Related Symptom Distress Scale - Change from Baseline in the weekly Opioid-Related Symptom Distress Scale at Weeks 2, 4, 8, 16, and 24.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events - Summary listing of adverse events for each participant; Summary of risk differences between each tanezumab group and placebo for common adverse events and for selected adverse events of interest.</outcome>
      <timepoint>Up to 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Standard safety assessments - Summary listing of safety laboratory testing [chemistry, hematology], sitting vital signs, ECG [12-lead]) for each participant.</outcome>
      <timepoint>Up to 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Orthostatic (supine/standing) blood pressure assessment - Orthostatic (supine/standing) blood pressure assessment.</outcome>
      <timepoint>Up to 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Weight and Height measurements, Physical examinations. - Weight measurements (pounds or kilograms), Height measurements (inches or centimeters), Body Mass Index (kg per meter squared), Physical examinations.</outcome>
      <timepoint>Up to 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Neurologic examination (Neuropathy Impairment Score [NIS]). - Neurologic examination (Neuropathy Impairment Score [NIS]).</outcome>
      <timepoint>Up to 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Survey of Autonomic Symptom scores - Survey of Autonomic Symptom scores.</outcome>
      <timepoint>Up to 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti-drug antibody (ADA) assessments - Anti-drug antibody (ADA) assessments.</outcome>
      <timepoint>Up to 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Joint safety adjudication outcomes - Number of subjects with adjudicated events of rapidly progressive osteoarthritis type 2, subchondral insufficiency fractures or spontaneous osteonecrosis of the knee, primary osteonecrosis, or pathological fracture.</outcome>
      <timepoint>Up to 48 weeks, or up to 24 weeks following total joint replacement procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total joint replacements - Total joint replacements</outcome>
      <timepoint>Up to 24 weeks post-procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Personally signed and dated informed consent document.

          -  Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
             and other study procedures.

          -  Male or female, =18 years of age

          -  Weight =40 kg at Screening

          -  Cancer diagnosed as having metastasized to bone or multiple myeloma.

          -  Imaging confirmation of bone metastasis at Screening or within 120 days prior to the
             Screening visit.

          -  Expected to require daily opioid medication throughout the course of the study.

          -  Willing to not use prohibited medications (including NSAIDs) throughout the duration
             of the study.

          -  Average Pain Score =5 at Screening for the index bone metastasis cancer pain site.

          -  Patient's Global Assessment of Cancer Pain of "fair", "poor" or "very poor" at
             Screening.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0, 1, or 2 at
             Screening.

          -  Adequate bone marrow, renal and liver function at Screening.

          -  International Normalized Ratio (INR) or prothrombin time (PT) &lt;1.5 x ULN at Screening
             unless being treated with anticoagulant medication.

          -  Females must either be not of childbearing potential or, if of childbearing potential
             and at risk for pregnancy, must be willing to use at least one highly effective method
             of contraception throughout the study and for 112 days (16 weeks) after the last dose
             of assigned subcutaneous study medication.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pain related to an oncologic emergency.

          -  Brain metastasis or leptomeningeal metastasis.

          -  Presence of hypercalcemia at Screening.

          -  Pain primarily classified as not predominantly related to a bone metastasis.

          -  Systemic treatment for the primary malignancy or bone metastasis started within 30
             days of the Baseline Assessment Period.

          -  In Japan only, chemotherapies associated with peripheral neuropathy (ie, paclitaxel,
             docetaxel, oxaliplatin, cisplatin, vincristine, thalidomide or bortezomib) are
             prohibited during study period from 30 days prior to the first day of the Baseline
             Assessment Period to Week 32.

          -  Receipt of radiopharmaceutical treatment or radiotherapy for treatment of bone
             metastasis within 30 days of the Baseline Assessment Period.

          -  Concurrent adjuvant analgesics unless started at least 30 days prior to the start of
             the Baseline Assessment Period and maintained at a stable dose.

          -  Diagnosis of osteoarthritis of the knee or hip or findings consistent with
             osteoarthritis in the shoulder.

          -  History of significant trauma or surgery to a major joint within one year prior to
             Screening.

          -  History of osteonecrosis or osteoporotic fracture.

          -  X-ray evidence at Screening of: 1) rapidly progressive osteoarthritis, 2) atrophic or
             hypotrophic osteoarthritis, 3) subchondral insufficiency fracture, 4) spontaneous
             osteonecrosis of the knee (SPONK), 5) osteonecrosis, or 6) pathologic fracture.

          -  Signs and symptoms of clinically significant cardiac disease.

          -  Evidence of orthostatic hypotension at Screening or at Baseline prior to
             randomization.

          -  Diagnosis of a transient ischemic attack in the 6 months prior to Screening or
             diagnosis of stroke with significant residual deficits.

          -  History, diagnosis, or signs and symptoms of clinically significant neurological
             disease.

          -  Total impact score of &gt;7 on the Survey of Autonomic Symptoms (SAS) at Screening.

          -  Past history of carpal tunnel syndrome (CTS) with signs or symptoms of CTS in the one
             year prior to Screening.

          -  History of significant alcohol, analgesic, or narcotic substance abuse within the six
             months prior to Screening.

          -  Planned surgical procedure during the duration of the study.

          -  Considered unfit for surgery or not willing to undergo joint replacement surgery if
             required.

          -  Known hypersensitivity to opioids or an underlying medical condition contraindicating
             opioid use.

          -  History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal
             antibody or IgG-fusion protein.

          -  Previous exposure to exogenous nerve growth factor or to an anti-nerve growth factor
             antibody.

          -  Presence of drugs of abuse, prescription medications without a valid prescription or
             other illegal drugs at Screening.

          -  Positive Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) tests at
             Screening indicative of current infection.

          -  Investigational site staff members and their family members, or Pfizer employees
             directly involved in the conduct of the trial.

          -  Participation in other studies involving investigational drug(s) within 30 days (or 90
             days for investigational biologics) before Baseline Assessment Period and/or during
             study participation.

          -  Pregnant female subjects; breastfeeding female subjects; female subjects of
             childbearing potential who are unwilling or unable to use one (1) highly effective
             method of contraception throughout the study and for 112 days after last dose of
             investigational product.

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>28/10/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>255</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>21/07/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Monash Medical Centre - Clayton</hospital>
    <hospital>Monash Medical Centre - East Bentleigh</hospital>
    <postcode>3168 - Clayton</postcode>
    <postcode>3165 - East Bentleigh</postcode>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Santa Fe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Caba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Krems</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Senftenberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RJ</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SC</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Region de La Araucania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Region Metropolitana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangdong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Heilongjiang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Henan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Hubei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Liaoning</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Zhejiang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Tianjin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Czech Republic</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Benesov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Horovice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Plzen - Bory</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Plzen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Pribram V - Zdabor</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Roche-Sur-Yon Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tarbes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Farkasgyepu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Miskolc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Nyiregyhaza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szekesfehervar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ashkelon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Beer Yaakov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Gunma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hyogo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Saga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Jung-gu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Silesia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Dabrowa Gornicza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gliwice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Katowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Dolj</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Timis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucuresti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Nove Zamky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Presov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Prešov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Pruské</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Žilina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Islas Baleares</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Scotland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Eli Lilly and Company</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether tanezumab is effective in the treatment of
      cancer pain due to bone metastasis in patients already taking background opioid therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02609828</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address />
      <phone>1-800-718-1021</phone>
      <fax />
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>